89284-05-9

Usage

Uses

Used in Pharmaceutical Industry:
4-Amino-3-bromo-5-nitropyridine is used as a building block for the synthesis of pharmaceuticals, contributing to the development of new drugs with potential therapeutic applications. Its unique structure allows for the creation of diverse biologically active molecules, enhancing the range of treatments available for various medical conditions.
Used in Agrochemical Industry:
In the agrochemical industry, 4-Amino-3-bromo-5-nitropyridine is used as a precursor in the synthesis of agrochemicals, such as pesticides and herbicides. Its ability to form various organic compounds makes it a valuable component in the development of effective and targeted agricultural products.
Used in Materials Science:
4-Amino-3-bromo-5-nitropyridine is used in materials science for the development of new materials with specific properties. Its potential application in this field is still under investigation, but it has shown promise in contributing to advancements in material technology.
Used as a Reagent in Organic Synthesis:
As a reagent in organic synthesis, 4-Amino-3-bromo-5-nitropyridine is utilized in various chemical reactions to produce a wide range of organic compounds. Its versatility and reactivity make it a valuable tool for chemists in the synthesis of complex molecules and the development of new chemical processes.

InChI:InChI=1/C5H4BrN3O2/c6-3-1-8-2-4(5(3)7)9(10)11/h1-2H,(H2,7,8)

Upstream product

• 31872-63-6 3-bromo-4-chloro-5-nitropyridine 
• 333-20-0 potassium thioacyanate 
• 64-19-7 acetic acid 
• 1681-37-4 4-amino-3-nitropyridine 
• 15367-14-3 4-Nitramino-3-brom-pyridin 
• 7726-95-6 bromine 
• 504-24-5 4-aminopyridine 
• 26482-55-3 4-(nitroamino)pyridine 
• 170158-64-2 4-(N-bromo-N-nitro)aminopyridine 

Downstream Products

• 4635-08-9 3,4-diamino-5-bromopyridine 
• 1214358-61-8 5-(3-fluorophenyl)pyridine-3,4-diamine 
• 1044771-99-4 5-bromo-N₄-methyl-pyridine-3,4-diamine 
• 1467083-71-1 N-(3-(4,5-diaminopyridin-3-yl)-5-fluorobenzyl)methanesulfonamide 
• 1467083-68-6 5-(3-((2-(dimethylamino)ethyl)amino)-5-fluorophenyl)pyridine-3,4-diamine 
• 1467083-65-3 N¹-(3-(4-amino-5-nitropyridin-3-yl)-5-fluorophenyl)-N²,N²-dimethylethane-1,2-diamine 
• 1357980-43-8 C₇H₅N₃O₂ 
• 1357980-36-9 C₂₁H₂₂N₄O₃ 
• 1357980-45-0 8-nitro-2-phenyl-1,6-naphthyridine 
• 1357981-12-4 7-nitro-2-[phenyl(piperidin-1-yl)methyl]-1H-pyrrolo[3,2-c]pyridine 
• 99000-51-8 8-bromo-2,3-diphenylpyrido[3,4-b]pyrazine 
• 163452-78-6 2-chloro-5-bromo-3,4-diaminopyridine 
• 1305317-08-1 8-bromo-2,3-bis(4-methoxyphenyl)pyrido[3,4-b]pyrazine 
• 1305317-28-5 N-(2,3-diphenylpyrido[3,4-b]pyrazin-8-yl)-4-methoxybenzamide 

Relevant academic research and scientific papers

FUSED RING COMPOUND, AND INTERMEDIATE THEREOF, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF

Provides a compound as shown in formula Ia or IB, a pharmaceutically acceptable salt thereof, a hydrate thereof, a solvate thereof, a polymorph thereof, a metabolite thereof, a stereoisomer thereof, an tautomer thereof, or a prodrug thereof. The compound as a Wnt inhibitor and mesenchymal stem cell inducer, sox9, type I collagen, X. collagen, osteogenetic transcription gene and alkaline phosphatase one or more have a good inducing effect, which can then be used to prepare drugs for the treatment and / or improvement of related diseases and disorders.

SOLID FORMS OF 1-(5-(3-(7-(3-FLUOROPHENYL)-3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDIN-5-YL)PYRIDIN-3-YL)-N,N-DIMETHYLMETHANAMINE

The present application relates to two crystalline polymorphic forms, crystalline methanol, ethanol and tetrahydrofuran solvates and a crystalline hydrate of the compound l-(5-(3-(7-(3-fluorophenyl)-3H- imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3- yl)-N,N-dimethylmethanamine (Ipivivint), to a pharmaceutical composition comprising them and their medical use for the treatment of disorders characterized by the activation of of the Wnt signaling pathway selected from cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease, osteoarthritis and idiopathic pulmonary fibrosis. Also claimed is a process for the preparation of compounds of Formula (I) by reacting a starting material of Formula (A1) with a compound of Formula (A2).

PYRAZOLE DERIVATIVES AS MODULATORS OF THE WNT/B-CATENIN SIGNALING PATHWAY

Pyrazole compounds (I) for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of a pyrazole compounds, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis Alzheimer's disease, lung disease, inflammation, auto-immune diseases and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as neurological conditions/disorders/diseases linked to overexpression of DYRK1A.

Identification of 2,4-Disubstituted Imidazopyridines as Hemozoin Formation Inhibitors with Fast-Killing Kinetics and in Vivo Efficacy in the Plasmodium falciparum NSG Mouse Model

A series of 2,4-disubstituted imidazopyridines, originating from a SoftFocus Kinase library, was identified from a high throughput phenotypic screen against the human malaria parasite Plasmodium falciparum. Hit compounds showed moderate asexual blood stage activity. During lead optimization, several issues were flagged such as cross-resistance against the multidrug-resistant K1 strain, in vitro cytotoxicity, and cardiotoxicity and were addressed through structure-Activity and structure-property relationship studies. Pharmacokinetic properties were assessed in mice for compounds showing desirable in vitro activity, a selectivity window over cytotoxicity, and microsomal metabolic stability. Frontrunner compound 37 showed good exposure in mice combined with good in vitro activity against the malaria parasite, which translated into in vivo efficacy in the P. falciparum NOD-scid IL-2Rnull (NSG) mouse model. Preliminary mechanistic studies suggest inhibition of hemozoin formation as a contributing mode of action.

3-(3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[4,3-B]PYRIDINES AND THERAPEUTIC USES THEREOF

4-Azaindazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of a 4-azaindazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

3-(3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINE AND THERAPEUTIC USES THEREOF

Azaindazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an azaindazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF

Indazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases due to mutations in Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF

Provided herein are compounds according to Formulas (I) or (II) and pharmaceutically acceptable salts thereof, and compositions comprising the same, for use in various methods, including treating cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease, osteoarthritis, idiopathic pulmonary fibrosis and neurological conditions/disorders/diseases.

INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF

Indazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt path

Efficient synthesis of aminomethylated azaindoles and corresponding pyrrole-fused derivatives by copper-catalyzed domino multicomponent coupling and cyclization

Efficient methods for the synthesis of aminomethylated azaindole derivatives via domino copper-catalyzed multicomponent coupling and cyclization have been developed. Using various secondary amines and aldehydes, N-substituted 3-ethynyl-4-aminopyridine was